SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
|Podcasts|May 10, 2023
The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes
Author(s)HCP Live Staff
Listen
0:00 / 0:00
Dermatologists Raj Chovatiya, MD, PhD, and David Rosmarin, MD, discuss new research outcomes for the topical JAK inhibitor live from the Revolutionizing Atopic Dermatiti 2023 Annual Meeting in Washington, DC.
Advertisement
David Rosmarin, MD, chair of the department of dermatology at Indiana University School of Medicine, joins Raj Chovatiya, MD, PhD, to review recent long-term extension data from the phase 3 TRuE-V clinical program, as well as what is expected next in ruxolitinib cream assessment for vitiligo.
Advertisement
Related to this article
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
4
Confounding Risk in Psilocybin Trial Comparators, With Josh Woolley, MD, PhD
5